Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
Prospective Observational Study on NovoSeven® Room Temperature Stable (VII25) in Patients With Haemophilia A or B
This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).
Reduced therapeutic response and neutralising antibodies to activated recombinant human factor VII as confirmed by central laboratory
Adverse events reported as potentially related to activated recombinant human factor VII
Congenital Bleeding Disorder
activated recombinant human factor VII
Study Arms / Comparison Groups
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - Diagnosed with congenital haemophilia A or B with inhibitors to factor VIII or factor IX - Treated with room temperature stable NovoSeven®
N/A - N/A
Accepts Healthy Volunteers
Global Clinical Registry (GCR, 1452), ,
Novo Nordisk A/S
Global Clinical Registry (GCR, 1452), Study Director, Novo Nordisk A/S